

DAFTAR PUSTAKA

- Amelot, A., De Cremoux, P., Quillien, V., Polivka, M., Adle-Biasette, H., Lehmann-Che, J., Françoise, L., Carpentier, A.F., George, B., Mandonnet, E., Froelich, S. (2015) 'IDH-mutation is a weak predictor of long-term survival in glioblastoma patients', *PLoS ONE*, 10(7).
- Van Den Bent, M.J., Dubbink, H.J., Marie, Y., Brandes, A.A., Taphoorn, M.J.B., Wesseling, P., Frenay, M., Tijssen, C.C., Lacombe, D., Idbaih, A., Van Marion, R., Kros, J.M., Dinjens, W.N.M., Gorlia, T., Sanson, M. (2010) 'IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendrogial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group', *Clinical Cancer Research*, 16(5), 1597–1604.
- Bleeker, F.E., Atai, N.A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K.S., Tigchelaar, W., Troost, D., Van Dertop, W.P., Bardelli, A., Van Noorden, C.J.F. (2010) 'The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma', *Acta Neuropathologica*, 119(4), 487–494.
- Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., Anjum, S., Wang, J., Manyam, G., Zoppoli, P., Ling, S., Rao, A.A., Grifford, M., Cherniack, A.D., Zhang, H., Poisson, L., Carlotti, C.G., Tirapelli, D.P.D.C., Rao, A., Mikkelsen, T., Lau, C.C., Yung, W.K.A., Rabadan, R., Huse, J., Brat, D.J., Lehman, N.L., Barnholtz-Sloan, J.S., Zheng, S., Hess, K., Rao, G., Meyerson, M., Beroukhi, R., Cooper, L., Akbani, R., Wrensch, M., Haussler, D., Aldape, K.D., Laird, P.W., Gutmann, D.H., Nushmeh, H., Iavarone, A., Verhaak, R.G.W. (2016) 'Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma', *Cell*, 164(3), 550–563.
- Christensen, B.C., Smith, A.A., Zheng, S., Koestler, D.C., Houseman, E.A., Marsit, C.J., Wiemels, J.L., Nelson, H.H., Karagas, M.R., Wrensch, M.R., Kelsey, K.T., Wiencke, J.K. (2011) 'DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma', *Journal of the National Cancer Institute*, 103(2), 143–153.
- Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., Marks, K.M., Prins, R.M., Ward, P.S., Yen, K.E., Liao, L.M., Rabinowitz, J.D., Cantley, L.C., Thompson, C.B., Vander Heiden, M.G., Su, S.M. (2010) 'Cancer-associated IDH1 mutations produce 2-hydroxyglutarate', *Nature*, 465(7300), 966–966, available: <http://www.nature.com/doi/10.1038/nature09132>.

- Efird, J.T. (2011) 'Epidemiology of Glioma', *Glioma - Exploring Its Biology and Practical Relevance*, (Cbtrus), 486, available: <http://www.intechopen.com/books/glioma-exploring-its-biology-and-practical-relevance>.
- Gravendeel, L.A.M., Kloosterhof, N.K., Bralten, L.B.C., Van Marion, R., Dubbink, H.J., Dinjens, W., Bleeker, F.E., Hoogenraad, C.C., Michiels, E., Kros, J.M., Van Den Bent, M., Smitt, P.A.E.S., French, P.J. (2010) 'Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma', *Human Mutation*, 31(3).
- Gupta, R., Webb-Myers, R., Flanagan, S., Buckland, M.E. (2011) 'Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications', *Journal of Clinical Pathology*, 64(10), 835–844, available: <http://jcp.bmj.com/cgi/doi/10.1136/jclinpath-2011-200227>.
- Hardiany, N.S., Sadikin, M., Wanandi, S.I. (2013) 'Ekspresi Relatif mRNA Hypoxia Inducible Factor-1 α pada Sel Glioma Penderita', *Indonesian Journal of Cancer*, 7(1), available: <http://indonesianjournalofcancer.or.id/e-journal/index.php/ijoc/article/view/272>.
- Hartmann, C., Hentschel, B., Simon, M., Westphal, M., Schackert, G., Tonn, J.C., Loeffler, M., Reifenberger, G., Pietsch, T., Von Deimling, A., Weller, M. (2013) 'Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations', *Clinical Cancer Research*, 19(18), 5146–5157.
- Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., Reifenberger, G., Weller, M., Loeffler, M., Von Deimling, A. (2010) 'Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas', *Acta Neuropathologica*, 120(6), 707–718.
- Horbinski, C., Kofler, J., Kelly, L.M., Murdoch, G.H., Nikiforova, M.N. (2009) 'Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues', *Journal of Neuropathology and Experimental Neurology*, 68(12), 1319–1325.
- Ichimura, K. (2012) 'Molecular pathogenesis of IDH mutations in gliomas', in *Brain Tumor Pathology*, 131–139.
- Juratli, T.A., Kirsch, M., Geiger, K., Klink, B., Leipnitz, E., Pinzer, T., Soucek, S., Schrok, E., Schackert, G., Krex, D. (2012) 'The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas',

Journal of Neuro-Oncology, 110(3), 325–333.

Karnofsky, D. a, Abelmann, W.H., Craver, L.F., Burchenal, J.H. (1948) ‘The use of the nitrogen mustards in the palliative treatment of carcinoma’, *Cancer*, 1(4), 634–656.

Kementrian Kesehatan Republik Indonesia (2015) *Panduan Nasional Penanganan Kanker Tumor Otak*, Komite Nasional Penanggulangan Kanker (KPKN).

Kim, S.R., Shin, Y.S., Kim, J.H., Choi, M., Yoo, S.H. (2017) ‘Differences in Type Composition of Symptom Clusters as Predictors of Quality of Life in Patients with Meningioma and Glioma’, *World Neurosurgery*, 98, 50–59.

Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W. (2016) ‘The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary’, *Acta Neuropathologica*.

Meng, J., Li, P., Zhang, Q., Yang, Z., Fu, S. (2014) ‘A radiosensitivity gene signature in predicting glioma prognostic via EMT pathway.’, *Oncotarget*, 5(13), 1, available: <http://europepmc.org/abstract/med/24970813>.

Mukasa, A., Takayanagi, S., Saito, K., Shibahara, J., Tabei, Y., Furuya, K., Ide, T., Narita, Y., Nishikawa, R., Ueki, K., Saito, N. (2012) ‘Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients’, *Cancer Science*, 103(3), 587–592.

Péus, D., Newcomb, N., Hofer, S. (2013) ‘Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation’, *BMC Medical Informatics and Decision Making*, 13(1), 72, available: <http://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/1472-6947-13-72>.

Raynaud, S., Carbuccion, N., Colin, C., Adélaïde, J., Mozziconacci, M.J., Metellus, P., Chinot, O., Birnbaum, D., Chaffanet, M., Figarella-Branger, D. (2010) ‘Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers’, *Oncology Letters*, 1(5), 883–884.

Reni, M., Mazza, E., Zanon, S., Gatta, G., Vecht, C.J. (2017) ‘Central nervous system gliomas’, *Critical Reviews in Oncology/Hematology*, 113, 213–234, available: <http://dx.doi.org/10.1016/j.critrevonc.2017.03.021>.

Sanson, M., Marie, Y., Paris, S., Idhah, A., Laffaire, J., Ducray, F., Hallani, S. El, Boisselier, B., Mokhtari, K., Hoang-Xuan, K., Delattre, J.Y. (2009)

‘Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas’, *Journal of Clinical Oncology*, 27(25), 4150–4154.

Sarkar, A., Chiocca, E.A. (2012) ‘Glioblastoma and Malignant Astrocytoma’, in *Brain Tumors*, 384–407.

Schag, C.C., Heinrich, R.L., Ganz, P.A. (1984) ‘Karnofsky performance status revisited: Reliability, validity, and guidelines’, *Journal of Clinical Oncology*, 2(3), 187–193.

Shibahara, I., Sonoda, Y., Kanamori, M., Saito, R., Kumabe, T., Tominaga, T. (2011) ‘New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status’, in *Brain Tumor Pathology*, 203–208.

Shibahara, I., Sonoda, Y., Kanamori, M., Saito, R., Yamashita, Y., Kumabe, T., Watanabe, M., Suzuki, H., Kato, S., Ishioka, C., Tominaga, T. (2012) ‘IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas’, *International Journal of Clinical Oncology*, 17(6), 551–561.

Songtao, Q., Lei, Y., Si, G., Yanqing, D., Huixia, H., Xuelin, Z., Lanxiao, W., Fei, Y. (2012) ‘IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma’, *Cancer Science*, 103(2), 269–273.

Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T.W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., Kool, M., Zapatka, M., Becker, N., Zucknick, M., Hielscher, T., Liu, X.Y., Fontebasso, A.M., Ryzhova, M., Albrecht, S., Jacob, K., Wolter, M., Ebinger, M., Schuhmann, M.U., van Meter, T., Frühwald, M.C., Hauch, H., Pekrun, A., Radlwimmer, B., Niehues, T., Von Komorowski, G., Dürken, M., Kulozik, A.E., Madden, J., Donson, A., Foreman, N.K., Drissi, R., Fouladi, M., Scheurlen, W., von Deimling, A., Monoranu, C., Roggendorf, W., Herold-Mende, C., Unterberg, A., Kramm, C.M., Felsberg, J., Hartmann, C., Wiestler, B., Wick, W., Milde, T., Witt, O., Lindroth, A.M., Schwartzentruber, J., Faury, D., Fleming, A., Zakrzewska, M., Liberski, P.P., Zakrzewski, K., Hauser, P., Garami, M., Klekner, A., Bognar, L., Morrissy, S., Cavalli, F., Taylor, M.D., van Sluis, P., Koster, J., Versteeg, R., Volckmann, R., Mikkelsen, T., Aldape, K., Reifenberger, G., Collins, V.P., Majewski, J., Korshunov, A., Lichter, P., Plass, C., Jabado, N., Pfister, S.M. (2012) ‘Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma’, *Cancer Cell*, 22(4), 425–437.

Tanaka, S., Kobayashi, I., Utsuki, S., Oka, H., Fujii, K., Watanabe, T., Nagashima, T., Hori, T. (2003) ‘O6-methylguanine-DNA methyltransferase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas’, *International Journal of Cancer*, 103(1),

67–72.

Turkalp, Z., Karamchandani, J., Das, S. (2014) ‘IDH Mutation in Glioma’, *JAMA Neurology*, 71(10), 1319, available: <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2014.1205>.

Uno, M., Oba-Shinjo, S.M., Silva, R. da, Miura, F., Clara, C.A., Almeida, J.R.W. de, Malheiros, S.M.F., Bianco, A.M., Brandt, R., Ribas, G.C., Feres, H., Dzik, C., Rosemberg, S., Stavale, J.N., Teixeira, M.J., Marie, S.K.N. (2011) ‘IDH1 mutations in a Brazilian series of Glioblastoma’, *Clinics*, 66(1), 163–165, available: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322011000100028&lng=en&nrm=iso&tlng=en.

Weller, M., Pfister, S.M., Wick, W., Hegi, M.E., Reifenberger, G., Stupp, R. (2013) ‘Molecular neuro-oncology in clinical practice: A new horizon’, *The Lancet Oncology*.

Widjanarko, A.S. (2011) *Angka Harapan Hidup Dua Tahun Penderita Low Grade Glioma Dan High Grade Glioma Yang Mendapatkan Terapi Radiasi*, Semarang.